ILMN Illumina, Inc.

All ILMN filings Filing statistics SEC Website

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Company profile

Ticker

ILMN

Exchange

NASDAQ

CEO

Francis A. deSouza

Incorporated in

Delaware

Location

California

Fiscal year end

Dec 29

Sector

Health Technology > Biotechnology

Industry (SEC)

Laboratory Analytical Instruments

PerkinElmer, Inc. • Waters • Bruker • Agilent • Coherent • Fluidigm • Harvard Bioscience • Pacific Biosciences of California • Quanterix • Accelerate Diagnostics ...

SEC CIK

0001110803

Corporate docs

Articles of Incorporation & Bylaws

IRS number

330804655

ILMN stock data

S&P 500 1 month 1 year

Company financial data Financial data

Chart ILMN financial data

Download latest Excel data (2019 Q1) View latest Excel data (2019 Q1)

Quarter (USD)	Mar 19	Dec 18	Sep 18	Jul 18
Revenue	846M	867M	853M	830M
Net income	233M	210M	199M	209M
Diluted EPS	1.57	1.41	1.33	1.41
Net profit margin	27.54%	24.22%	23.33%	25.18%
Operating income	204M	197M	241M	227M
Net change in cash		-202M	2M	-216M
Cash on hand		1.14B	1.35B	1.34B
Cost of revenue	262M	277M	256M	255M

Financial data from Illumina earnings reports

Financial report summary

Competition

Thermo Fisher Scientific • BGI • Ceres • Roche Holding • Solexa • Qiagen • Luminex • Biocept • Agilent • Third Wave

Management Discussion

To enhance comparability, the following table sets forth unaudited condensed consolidated statement of operations data for the specified reporting periods, stated as a percentage of total revenue.
Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three-month periods ended March 31, 2019 and April 1, 2018 were both 13 weeks.
Service and other revenue consists primarily of sequencing and genotyping service revenue as well as instrument service contract revenue. Total revenue primarily relates to Core Illumina for all periods presented.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abatement, accurate, acquisition, agreement, antitrust, began, borrowing, British, broaden, California, competition, comprised, customary, derecognition, derecognized, estate, evidence, exposure, extension, fee, feet, implicit, incremental, lab, licensing, long, maximum, merger, NextSeq, November, owed, PacBio, Pacific, past, perfect, pound, predominantly, prepaid, real, receipt, recommendation, regulatory, relinquish, rent, rental, repay, satisfaction, scalable, security, square, sublease, superior, tenant, termination, Unrealized, view, withdrawal

Removed: absorbed, acceptable, alternative, applying, blood, cancer, ceased, charge, claim, committee, comparative, controlling, created, cumulative, deconsolidated, detection, enacted, enactment, entitled, estimating, expedient, extent, finalize, freight, gathered, GILTI, goodwill, granted, guidance, hand, HiSeq, identifiable, impaired, improved, incomplete, indefinitely, indemnification, individually, intangible, interpret, interpretation, lacked, law, legislation, length, maturity, meaningful, opening, opposing, orderly, original, owner, performed, preferred, pretax, principle, proceeding, projected, promised, proportional, prospectively, provision, provisional, reached, reassessed, recording, recoverability, reduced, reliable, remeasured, removed, representation, revision, section, substantially, Subtopic, succeed, superseded, test, transition, treatment, trend, trial, ultimately, unable, unique, unsatisfied, validation

From filing 10-Q 2019 Q1